Federated Hermes’s Apellis Pharmaceuticals APLS Stock Holding History

Federated Hermes’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-147,465	Closed	-$13.4M	–	2095
2023 Q2	$13.4M	Sell	147,465 -363,837	-71%	-$31.4M	0.03%	478
2023 Q1	$33.7M	Buy	511,302 +75,002	+17%	+$4.33M	0.08%	270
2022 Q4	$22.6M	Buy	436,300 +85,197	+24%	+$4.52M	0.06%	353
2022 Q3	$24M	Buy	+351,103	New	+$20.8M	0.07%	336
2021 Q4	–	Sell	-3,497	Closed	-$115K	–	2204
2021 Q3	$115K	Sell	3,497 -233,757	-99%	-$13.1M	﹤0.01%	1753
2021 Q2	$15M	Buy	237,254 +184,588	+350%	+$9.52M	0.03%	548
2021 Q1	$2.26M	Sell	52,666 -64,564	-55%	-$3.05M	﹤0.01%	1068
2020 Q4	$6.71M	Buy	+117,230	New	+$4.96M	0.01%	733
2020 Q1	–	Sell	-1,434	Closed	-$44K	–	2239
2019 Q4	$44K	Sell	1,434 -163,197	-99%	-$4.52M	﹤0.01%	1751
2019 Q3	$3.97M	Buy	164,631 +163,217	+11,543%	+$4.49M	0.01%	829
2019 Q2	$36K	Sell	1,414 -195	-12%	-$3.97K	﹤0.01%	1721
2019 Q1	$31K	Sell	1,609 -146	-8%	-$2.3K	﹤0.01%	1706
2018 Q4	$23K	Sell	1,755 -562	-24%	-$8.62K	﹤0.01%	1740
2018 Q3	$41K	Sell	2,317 -1,010	-30%	-$18.7K	﹤0.01%	1760
2018 Q2	$73K	Buy	3,327 +283	+9%	+$6.5K	﹤0.01%	1642
2018 Q1	$67K	Buy	+3,044	New	+$59.8K	﹤0.01%	1628

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes's APLS Position: Q3 2023 in Review

Federated Hermes sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 147,465 shares — an estimated $13.4M sold.

Federated Hermes first reported a position in APLS in Q1 2018 and held it in 16 quarters. The position peaked at $33.7M in Q1 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

Federated Hermes reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Federated Hermes sold 147,465 Apellis Pharmaceuticals shares in Q3 2023, an estimated $13.4M.
Federated Hermes first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 16 quarters.
Federated Hermes's Apellis Pharmaceuticals position peaked at $33.7M in Q1 2023.
256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.